<![CDATA[Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=41106>Sun, 19 Apr 2026 04:18:56 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond]]>https://www.newswire.co.kr/newsRead.php?no=1031632Thu, 02 Apr 2026 14:30:00 +0900<![CDATA[바이오사이토젠-스환 파마슈티컬, 체중 감량 및 폭넓은 질환 치료를 위한 전략적 파트너십 체결]]>https://www.newswire.co.kr/newsRead.php?no=1031633Thu, 02 Apr 2026 14:30:00 +0900<![CDATA[Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform]]>https://www.newswire.co.kr/newsRead.php?no=1031362Tue, 31 Mar 2026 09:30:00 +0900<![CDATA[바이오사이토젠-다이쇼 제약, RenNano® 전인체성 단일 중쇄 항체 발견 플랫폼에 대한 사용 허가 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1031365Tue, 31 Mar 2026 09:30:00 +0900<![CDATA[Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=1031253Sun, 29 Mar 2026 10:25:00 +0900<![CDATA[바이오사이토젠, 파트너사 NEOK 바이오의 고형암 표적 치료제 NEOK002에 대한 FDA IND 승인 발표]]>https://www.newswire.co.kr/newsRead.php?no=1031254Sun, 29 Mar 2026 10:25:00 +0900<![CDATA[Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders]]>https://www.newswire.co.kr/newsRead.php?no=1030940Tue, 24 Mar 2026 15:20:00 +0900<![CDATA[바이오사이토젠-문라이트 바이오, 항체 바인더 라이브러리 활용 세포 치료제 개발 협력]]>https://www.newswire.co.kr/newsRead.php?no=1030941Tue, 24 Mar 2026 15:20:00 +0900<![CDATA[Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034]]>https://www.newswire.co.kr/newsRead.php?no=1029532Tue, 03 Mar 2026 14:20:00 +0900<![CDATA[바이오사이토젠, 아이디야의 동종 최초의 B7H3/PTK7 이중특이적 TOP1 ADC IDE034의 제1상 임상시험 첫 환자 투여 완료에 따른 임상적 이정표 발표]]>https://www.newswire.co.kr/newsRead.php?no=1029533Tue, 03 Mar 2026 14:20:00 +0900<![CDATA[Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)]]>https://www.newswire.co.kr/newsRead.php?no=1026851Tue, 13 Jan 2026 14:00:00 +0900<![CDATA[바이오사이토젠-아세포디아, 계열 내 최초 이중특이성 이중 페이로드 BsAD2C 개발 위한 옵션 기반 평가 프레임워크로 협력 확대]]>https://www.newswire.co.kr/newsRead.php?no=1026853Tue, 13 Jan 2026 14:00:00 +0900<![CDATA[Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator]]>https://www.newswire.co.kr/newsRead.php?no=1025200Fri, 12 Dec 2025 10:00:00 +0900<![CDATA[바이오사이토젠, 커촹반 상장 완료… 최초의 ‘H+A’ 글로벌 신약 혁신 기업으로 도약]]>https://www.newswire.co.kr/newsRead.php?no=1025201Fri, 12 Dec 2025 10:00:00 +0900<![CDATA[IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance]]>https://www.newswire.co.kr/newsRead.php?no=1024753Fri, 05 Dec 2025 17:15:00 +0900<![CDATA[IDE034, FDA IND 승인 획득]]>https://www.newswire.co.kr/newsRead.php?no=1024754Fri, 05 Dec 2025 17:15:00 +0900<![CDATA[Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody]]>https://www.newswire.co.kr/newsRead.php?no=1018897Wed, 17 Sep 2025 10:05:00 +0900<![CDATA[바이오사이토젠-ADC 개발사 튜불리스, 단일 항체 글로벌 독점 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1018900Wed, 17 Sep 2025 10:05:00 +0900<![CDATA[바이오사이토젠, 항체 접합 지질 기반 전달 솔루션 발전을 위해 머크와 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1018176Fri, 05 Sep 2025 17:15:04 +0900<![CDATA[Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions]]>https://www.newswire.co.kr/newsRead.php?no=1018175Fri, 05 Sep 2025 17:15:00 +0900<![CDATA[Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website]]>https://www.newswire.co.kr/newsRead.php?no=1015729Tue, 29 Jul 2025 10:55:00 +0900<![CDATA[바이오사이토젠, 전임상 서비스 플랫폼 업그레이드 및 개편된 글로벌 웹사이트 오픈]]>https://www.newswire.co.kr/newsRead.php?no=1015731Tue, 29 Jul 2025 10:55:00 +0900<![CDATA[Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development]]>https://www.newswire.co.kr/newsRead.php?no=1014764Fri, 11 Jul 2025 10:20:00 +0900<![CDATA[바이오사이토젠, 혁신적인 약물 개발을 가속화하기 위해 비원 메디신스와 항체 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1014765Fri, 11 Jul 2025 10:20:00 +0900<![CDATA[Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform]]>https://www.newswire.co.kr/newsRead.php?no=1012638Sun, 08 Jun 2025 11:20:00 +0900